8-K current report · filed Aug 3, 2026

Crinetics Pharmaceuticals, Inc. (CRNX) 8-K Current Report: August 3, 2026

Item 2.02Item EX-99.1CRNX overview

Short answer

Crinetics Pharmaceuticals, Inc. (CRNX) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Crinetics reported financial results for the period ended June 30, 2026.

Crinetics Pharmaceuticals, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Crinetics reported financial results for the period ended June 30, 2026
  • Full results and management commentary available in Exhibit 99.1
  • Press release furnished under Item 2.02, limiting Exchange Act Section 18 liability

Item EX-99.1 · Exhibit EX-99.1

  • Vertex acquisition at $85.00 per share, approximately $10.0B equity value, expected closing in Q3 2026 subject to approvals
  • PALSONIFY net product revenue $24.0M, up from $10.3M in Q1 2026, signaling accelerating commercial adoption
  • 70%+ of PALSONIFY patients on reimbursed therapy, reducing near-term access risk for the commercial launch
  • Q2 revenue $25.1M versus $1.0M prior-year, while net loss reached $120.9M amid $99.9M R&D and $57.6M SG&A
  • Cash, cash equivalents and investments totaled $1.2B at June 30, 2026, supporting operations through the proposed transaction process

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Crinetics Pharmaceuticals, Inc. 8-K filings

Get the next CRNX 8-K as it lands

Follow CRNX for push alerts, or ask the research agent what this filing means.